High-parametric flow cytometry cell sorter for human immunology studies.
用于人类免疫学研究的高参数流式细胞仪细胞分选仪。
基本信息
- 批准号:10632888
- 负责人:
- 金额:$ 81.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-15 至 2024-08-14
- 项目状态:已结题
- 来源:
- 关键词:Antigen PresentationAutomobile DrivingB-LymphocytesBasic ScienceBooksCell SeparationCell SurvivalCellsChildhoodClinical ResearchCloningCommunitiesDedicationsDisciplineFlow CytometryFundingHIVHumanImmuneImmune responseImmunityImmunologic MonitoringImmunologyIndividualInfectionInvestigationLasersLeadershipMedical centerMinorNecrosisOrganPathogenesisPatientsPeripheralPopulationResearchResearch PersonnelSamplingScientistSiteStreamStructure of germinal center of lymph nodeSurveysT-LymphocyteTechnologyTissuesTranslational ResearchUnited States National Institutes of HealthWorkequipment acquisitioninsightinstrumentinstrumentationmedical schoolsprospectivetooltumorvaccine response
项目摘要
PROJECT SUMMARY
Flow cytometry is the most commonly used and critical tool for analyzing immune cell populations in tissues,
enabling approximately 18-20 parameter separation of populations and maintaining cell viability. By passing cells
through a stream in which laser excitation is applied, individual populations of cells can be separated into either
96 well plates as single cells, enabling cloning and other applications, or can be enriched as populations in 4-6
separate populations simultaneously. This is the only cell separation technology universally adaptable to multiple
tissues including isolation of rare populations from difficult sites such as peripheral tissues, necrotic tumors, and
organs.
Currently, this cutting-edge technology is not readily available to the Weill Cornell Medical College (WCMC) and
medical center research community. Our current flow cytometry core is at maximum capacity usage for basic
science applications and is booked weeks to months in advance, prohibiting alignment to the needs of clinical
research investigators and basic and translational research directly on patient samples.
Based on a prospective survey of WCMC scientists, we have identified over 12 NIH-funded major users, as well
as a large number of minor users from multiple departments who have requested this instrumentation to advance
their work. The proposed applications are diverse, leveraging the various scientific strengths of a number of
WCMC labs. Some examples include Dr. Ari Melnick's work on understanding human B cell germinal centers,
Dr. Sallie Permar’s understanding of pediatric infections and human vaccine responses and correlates of
protective immunity, Dr. Laura Santambrogio’s ongoing studies on the human MHC peptidome to understand
immune antigen presentation, and Dr. Brad Jones’ investigations into HIV pathogenesis and T cell immune
responses.
The leadership of WCMC is strongly supportive of the acquisition of this instrument, and will provide significant
additional funds beyond those requested in the S10 application. In addition, dedicated space has been allocated
within the Belfer Research Building and Human Immune Monitoring Core, where the instrument will be located
and managed. Overall, we hypothesize that the establishment of a Flow Cytometry cell sorter instrument on the
WCMC campus will be pivotal in driving new scientific insights across a number of projects and disciplines.
项目摘要
流式细胞仪是最常用和最关键的工具,用于分析组织中的免疫群群体,
实现大约18-20个种群的参数分离并维持细胞活力。通过通过细胞
通过应用激光兴奋的流,可以将单个细胞种群分为
96个井板作为单个单元,启用克隆和其他应用,或者可以在4-6中富集为种群
单独的人群。这是唯一普遍适用于多个的细胞分离技术
组织,包括从困难地点分离稀有种群的组织,例如外周组织,坏死肿瘤和
器官。
目前,Weill Cornell医学院(WCMC)和
医疗中心研究社区。我们当前的流式细胞仪核心的最大容量用途
科学应用程序并提前几个月预订,禁止对临床需求保持一致
研究人员以及基本和翻译的研究直接研究了患者样本。
根据对WCMC科学家的预期调查,我们还确定了超过12位由NIH资助的主要用户
作为来自多个部门的大量未成年人,他们要求此工具提前
他们的工作。拟议的应用是潜水员,利用了许多的各种科学优势
WCMC实验室。一些例子包括阿里·梅尔尼克(Ari Melnick)博士了解人类B细胞生发中心的工作,
Sallie Permar博士对小儿感染和人类疫苗反应的理解以及
保护性免疫,Laura Santambrogio博士正在进行的关于人类MHC胡椒的研究
免疫抗原表现,布拉德·琼斯(Brad Jones)博士对HIV发病机理和T细胞免疫的研究
回答。
WCMC的领导能够强烈支持该工具的获取,并将提供重要的
额外的资金超出了S10应用程序中要求的资金。此外,专门的空间已分配
在Belfer研究大楼和人类免疫监测核心中,该仪器将位于该仪器
并管理。总体而言,我们假设建立流式细胞仪细胞分散器仪器
WCMC校园将在推动许多项目和学科的新科学见解方面至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Niroshana Anandasabapathy其他文献
Niroshana Anandasabapathy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Niroshana Anandasabapathy', 18)}}的其他基金
Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance
探究 DC 对组织的独特适应,以促进屏障免疫和耐受性
- 批准号:
10378337 - 财政年份:2022
- 资助金额:
$ 81.69万 - 项目类别:
Interrogating unique DC adaptations to tissue to promote barrier immunity and tolerance
探究 DC 对组织的独特适应,以促进屏障免疫和耐受性
- 批准号:
10579963 - 财政年份:2022
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
9684364 - 财政年份:2018
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
9768889 - 财政年份:2018
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
10004498 - 财政年份:2018
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
9397655 - 财政年份:2016
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
9258870 - 财政年份:2016
- 资助金额:
$ 81.69万 - 项目类别:
Peripheral mechanisms of homeostasis and tolerance through skin dendritic cells
通过皮肤树突状细胞实现稳态和耐受的外周机制
- 批准号:
9353720 - 财政年份:2016
- 资助金额:
$ 81.69万 - 项目类别:
The clinical use of Flt3L - an immune adjuvant to potentiate Dendritic Cells
Flt3L——增强树突状细胞免疫佐剂的临床应用
- 批准号:
8609183 - 财政年份:2012
- 资助金额:
$ 81.69万 - 项目类别:
The clinical use of Flt3L - an immune adjuvant to potentiate Dendritic Cells
Flt3L——增强树突状细胞免疫佐剂的临床应用
- 批准号:
9096028 - 财政年份:2012
- 资助金额:
$ 81.69万 - 项目类别:
相似国自然基金
基于驾驶人行为理解的人机共驾型智能汽车驾驶权分配机制研究
- 批准号:52302494
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
有条件自动驾驶汽车驾驶人疲劳演化机理与协同调控方法
- 批准号:52372341
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
人机共驾汽车驾驶风险分析及控制权智能交互机理
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
人机共驾汽车驾驶风险分析及控制权智能交互机理
- 批准号:52272413
- 批准年份:2022
- 资助金额:54.00 万元
- 项目类别:面上项目
定性与定量分析跟驰行驶中汽车驾驶员情感-行为交互作用机理
- 批准号:71901134
- 批准年份:2019
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of SH2B3 in regulating CD8 T cells in Type 1 Diabetes
SH2B3 在 1 型糖尿病中调节 CD8 T 细胞的作用
- 批准号:
10574346 - 财政年份:2023
- 资助金额:
$ 81.69万 - 项目类别:
Role of TLR7-mediated B cell activation in primary Sjogren’s syndrome
TLR7 介导的 B 细胞激活在原发性干燥综合征中的作用
- 批准号:
10676443 - 财政年份:2023
- 资助金额:
$ 81.69万 - 项目类别:
Leveraging Human iPSC-derived beta-cells to Probe Antigen Specificity of Anti-islet Memory T Cells in T1D
利用人 iPSC 衍生的 β 细胞探测 T1D 中抗胰岛记忆 T 细胞的抗原特异性
- 批准号:
10589556 - 财政年份:2023
- 资助金额:
$ 81.69万 - 项目类别:
Targeting the immunoproteasome as a novel therapeutic strategy for hemophagocytic lymphohistiocytosis
靶向免疫蛋白酶体作为噬血细胞性淋巴组织细胞增多症的新型治疗策略
- 批准号:
10741624 - 财政年份:2023
- 资助金额:
$ 81.69万 - 项目类别:
CAR-T cell treatment of CNS Autoimmunity
CAR-T细胞治疗中枢神经系统自身免疫
- 批准号:
10641913 - 财政年份:2022
- 资助金额:
$ 81.69万 - 项目类别: